Global Opioid Induced Constipation Market Share

Statistics for the 2023 & 2024 Global Opioid Induced Constipation market share, created by Mordor Intelligence™ Industry Reports. Global Opioid Induced Constipation share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Tranquilizers Research Opioids Research Opioid Induced Constipation Industry Market Share

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Global Opioid Induced Constipation Industry

The Opioid Induced Constipation market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, while others are developing new methods for the treatment and introducing new products to maintain their market share. A few of the major players currently dominating the industry in terms of revenue are AstraZeneca plc, Mallinckrodt Pharmaceuticals, Bausch Health (Salix Pharmaceuticals Inc), Merck & Co Inc, and Shionogi & Co Ltd.

Opioid Induced Constipation (OIC) Market Leaders

  1. AstraZeneca plc

  2. Merck & Co Inc

  3. Shionogi & Co Ltd

  4. Mallinckrodt Pharmaceuticals

  5. Bausch Health ( Salix Pharmaceutical Inc.)

*Disclaimer: Major Players sorted in no particular order

CL-OICM.png

Opioid-Induced Constipation Market Report Snapshots

Opioid-Induced Constipation Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)